Outcome Measures to Assess Efficacy of Treatments for Age-Related Macular Degeneration

Ophthalmology

Volumn 116, Issue 10 SUPPL., 2009, Pages

  Wittes, Janet ^a   Downs, Matthew ^a  

^a University of Iowa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BINARY VARIABLE; CONTINUOUS VARIABLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; HUMAN; MATHEMATICAL ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; STATISTICAL ANALYSIS; THREE CATEGORY VARIABLE; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; OUTCOME ASSESSMENT (HEALTH CARE); SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME; VISION, OCULAR; VISUAL ACUITY;

EID: 70349446589     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.06.050     Document Type: Article

References (16)

1. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119 (2001) 1417-1436
2. Evans J.R. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 2 (2006)
3. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
4. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
5. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
6. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
7. Nicolo M., Ghiglione D., Lai S., and Calabria G. Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1336-1338
8. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
9. Wittes J. Sample size calculations for randomized controlled trials. Epidemiol Rev 24 (2002) 39-53
10. Beck R.W., Maguire M.G., Bressler N.M., et al. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology 114 (2007) 1804-1809
11. Regillo C.D., Brown D.M., Abraham P., et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145 (2008) 239-248
12. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131 (2001) 541-560
13. Verbeke G., and Molenberghs G. Linear Mixed Models in Practice: A SAS-Oriented Approach (1997), Springer, New York
14. Whitehead J. Sample size calculations for ordered categorical data. Stat Med 12 (1993) 2257-2271
15. Walters S.J. Sample size and power estimation for studies with health related quality of life outcomes: a comparison of four methods using the SF-36. Health Qual Life Outcomes 2 (2004) 26
16. Cleland J.G., Freemantle N., Coletta A.P., and Clark A.L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 8 (2006) 105-110